---
title: "Eli Lilly's orforglipron has reduced the weight of adult obesity patients by 11.2%"
description: "At the European Association for the Study of Diabetes meeting held in Vienna, Eli Lilly's weight loss drug orforglipron reduced the weight of obese adult patients by 11.2% in a large clinical trial. D"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/257614618.md"
published_at: "2025-09-16T22:04:45.000Z"
---

# Eli Lilly's orforglipron has reduced the weight of adult obesity patients by 11.2%

> At the European Association for the Study of Diabetes meeting held in Vienna, Eli Lilly's weight loss drug orforglipron reduced the weight of obese adult patients by 11.2% in a large clinical trial. Doctors stated that this achievement is significant for patients and will have a profound impact on the field of weight loss medications. The drug's side effects are consistent with currently available vaccines, and Eli Lilly also presented the full data from the major obesity trial at the meeting, which was published in the New England Journal of Medicine

Doctors said that in a large clinical trial, Eli Lilly's weight loss drug significantly reduced patients' weight, which is of great importance to patients and has a profound impact on the field.

At the European Association for the Study of Diabetes meeting held in Vienna, doctors reported that the American pharmaceutical company's tablet orforglipron reduced the weight of adult obese patients by 11.2%, and the side effects were consistent with currently available vaccines.

Eli Lilly presented the full data from the drug's main obesity trial at the conference and published it in the New England Journal of Medicine

### Related Stocks

- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Eli Lilly (LLY) Builds $1.5 Billion Inventory of Weight-Loss Pill | Eli Lilly (LLY) has prepared a $1.5 billion inventory of its new weight-loss pill, Orforglipron, ahead of its anticipate | [Link](https://longbridge.com/en/news/276070062.md) |
| DELL, SPOT, UNH: The World's Biggest Hedge Fund Is Bottom Fishing the Market | Bridgewater Associates, the largest hedge fund with $136 billion in assets, made significant investments in underperform | [Link](https://longbridge.com/en/news/276384705.md) |
| Eli Lilly and Company $LLY Shares Acquired by Assetmark Inc. | Assetmark Inc. increased its holdings in Eli Lilly and Company (NYSE: LLY) by 6.0% in Q3, owning 55,360 shares valued at | [Link](https://longbridge.com/en/news/275971336.md) |
| Broderick Brian C Purchases 985 Shares of Eli Lilly and Company $LLY | Broderick Brian C increased its stake in Eli Lilly and Company (NYSE: LLY) by 15.1% in Q3, acquiring 985 additional shar | [Link](https://longbridge.com/en/news/276435096.md) |
| Vanda Pharmaceuticals announces FDA approval of Bysanti tablets | Vanda Pharmaceuticals announces FDA approval of Bysanti tablets | [Link](https://longbridge.com/en/news/276504017.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
